The objective of this study was to determine the effects of Imrecoxib, an anti-infiammatory/analgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of warfarin in healthy volunteers.
This is a single center open label study to assess the effect of Imrecoxib on the PK of Warfarin in Healthy Volunteers. The goals of this study are as follows: assess the PK of warfarin when administered alone ,and with Imrecoxib ; assess INR of warfarin when administered alone, and with Imrecoxib; to assess the effect of Imrecoxib on the PK/PD of warfarin, to assess the safety and tolerability of warfarin administered with Imrecoxib.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, Hubei, China
Pharmacokinetics parameters like Cmax、tmax and AUC0-t of Warfarin
Time frame: Predose up to 144 hours post Day 1 and Day 10 dose
Prothrombintime after Warfarin dosing
Time frame: 6 hours to 144 hours post Day 1 and Day10 dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.